EU nod for Novo’s long-acting haemophilia drug
Novo Nordisk says it expects to launch its long-acting haemophilia B drug Refixia in the European Union in the fourth quarter of this year after receiving a green light from regulators.
Read More
Tag: nonacog beta pegol
Six new medicines backed for EU approval
Six new medicines, including three orphan drugs for rare diseases, have been backed for European Union approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
